RNA interference in the clinic: Challenges and future directions

Nature Reviews Cancer

Volumn 11, Issue 1, 2011, Pages 59-67

  Pecot, Chad V ^a   Calin, George A ^b,c   Coleman, Robert L ^b,c   Lopez Berestein, Gabriel ^a,b,c   Sood, Anil K ^b,c  

^a Division of Cancer Medicine   (United States)

^b Center for RNA Interference and Non Coding RNA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; MACROGOL; NANOPARTICLE; RNA; SMALL INTERFERING RNA;

CANCER GENE THERAPY; DRUG HALF LIFE; DRUG MECHANISM; GENE SILENCING; GENE TARGETING; HUMAN; IMMUNOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; RNA INTERFERENCE;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 78650624101     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2966     Document Type: Review

References (99)

1. Fire, A. et al. Potent and specific genetic interference by double-strandedRNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). (Pubitemid 28099681)
2. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
3. Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007).
4. Kikani, C. K., Dong, L. Q. & Liu, F. "New"-clear functions of PDK1: beyond a master kinase in the cytosol? J. Cell. Biochem. 96, 1157-1162 (2005).
5. Lim, S. T., Mikolon, D., Stupack, D. G. & Schlaepfer, D. D. FERM control of FAK function: implications for cancer therapy. Cell Cycle 7, 2306-2314 (2008).
6. Weihua, Z. et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393 (2008).
7. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010). This is the first report of using targeted nanoparticles for siRNA delivery in humans.
8. Sashital, D. G. & Doudna, J. A. Structural insights into RNA interference. Curr. Opin. Struct. Biol. 20, 90-97 (2010).
9. Rana, T. M. Illuminating the silence: understanding the structure and function of small RNAs. Nature Rev. Mol. Cell Biol. 8, 23-36 (2007).
10. Heo, I. & Kim, V. N. Regulating the regulators: posttranslational modifications of RNA silencing factors. Cell 139, 28-31 (2009).
11. Hannon, G. J. & Rossi, J. J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
12. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
13. Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 565-574 (2002).
14. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
15. Meister, G. et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185-197 (2004).
16. Kim, V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nature Rev. Mol. Cell Biol. 6, 376-385 (2005).
17. Bohnsack, M. T., Czaplinski, K. & Gorlich, D. Exportin-5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185-191 (2004).
18. Chu, C. & Rana, T. M. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol. 4, e210 (2006).
19. Fabbri, M. & Calin, G. A. Beyond genomics: interpreting the 93% of the human genome that does not encode proteins. Curr. Opin. Drug Discov. Devel. 13, 350-358.
20. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711-719 (2006).
21. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
22. Czauderna, F. et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716 (2003).
23. Kim, D. H. & Rossi, J. J. Strategies for silencing human disease using RNA interference. Nature Rev. Genet. 8, 173-184 (2007).
24. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B. & McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487-495 (2008).
25. Skinner, S. A., Tutton, P. J. & O'Brien, P. E. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50, 2411-2417 (1990).
26. Decuzzi, P., Causa, F., Ferrari, M. & Netti, P. A. The effective dispersion of nanovectors within the tumor microvasculature. Ann. Biomed. Eng. 34, 633-641 (2006).
27. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
28. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
29. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21, 797-802 (2010).
30. Decuzzi, P. & Ferrari, M. The receptor-mediated endocytosis of nonspherical particles. Biophys. J. 94, 3790-3797 (2008).
31. Dominska, M. & Dykxhoorn, D. M. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123, 1183-1189 (2010).
32. Kleeff, J. et al. Pancreatic cancer microenvironment. Int. J. Cancer 121, 699-705 (2007).
33. Burke, R. S. & Pun, S. H. Extracellular barriers to in Vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjug. Chem. 19, 693-704 (2008).
34. Goodman, T. T., Ng, C. P. & Pun, S. H. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjug. Chem. 19, 1951-1959 (2008).
35. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1477-1478 (2004).
36. Bartneck, M., Keul, H. A., Zwadlo-Klarwasser, G. & Groll, J. Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett. 10, 59-63 (2010).
37. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotech. 23, 457-462 (2005).
38. Forsbach, A. et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180, 3729-3738 (2008).
39. Jackson, A. L. & Linsley, P. S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Rev. Drug Discov. 9, 57-67 (2010).
40. Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89-101 (2009).
41. Kleinman, M. E. et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
42. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737 (2004).
43. Sakamoto, J. H. et al. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 1-31 (2010).
44. Ma, Z. et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755-759 (2005).
45. Omidi, Y., Barar, J. & Akhtar, S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr. Drug Deliv. 2, 429-441 (2005).
46. Dokka, S., Toledo, D., Shi, X., Castranova, V. & Rojanasakul, Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17, 521-525 (2000).
47. Gutierrez-Puente, Y. et al. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk. Lymphoma 44, 1979-1985 (2003).
48. Landen, C. N. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
49. Ahmed, A. A. et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18, 109-121 (2010).
50. Schroeder, A., Levins, C. G., Cortez, C., Langer, R. & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267, 9-21 (2010).
51. Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W. & Park, T. G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129, 107-116 (2008).
52. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotech. 25, 1149-1157 (2007).
53. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotech. 26, 561-569 (2008).
54. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864-1869 (2010).
55. Hunter, A. C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 58, 1523-1531 (2006).
56. Jain, K., Kesharwani, P., Gupta, U. & Jain, N. K. Dendrimer toxicity: let's meet the challenge. Int. J. Pharm. 394, 122-142 (2010).
57. Pille, J. Y. et al. Intravenous delivery of anti-RhoA small interfering RNA Loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17, 1019-1026 (2006).
58. Han, H. D. et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 16, 3910-3922 (2010).
59. Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197 (2010).
60. Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715-5721 (2007).
61. Takeshita, F. et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182 (2005).
62. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotech. 21, 635-637 (2003).
63. Jackson, A. L. et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006).
64. Farh, K. K. et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817-1821 (2005).
65. Jackson, A. L. et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205 (2006).
66. Merritt, W. M. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641-2650 (2008).
67. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
68. Castanotto, D. et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 35, 5154-5164 (2007).
69. Khan, A. A. et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotech. 27, 549-555 (2009).
70. Haley, B. & Zamore, P. D. Kinetic analysis of the RNAi enzyme complex. Nature Struct. Mol. Biol. 11, 599-606 (2004).
71. Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N. & De Smedt, S. C. Maintaining the silence: reflections on long-term RNAi. Drug Discov. Today 13, 917-931 (2008).
72. Takabatake, Y. et al. Chemically modified siRNA prolonged RNA interference in renal disease. Biochem. Biophys. Res. Commun. 363, 432-437 (2007).
73. Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 31, 322-333 (2006).
74. Duncan, R. The dawning era of polymer therapeutics. Nature Rev. Drug Discov. 2, 347-360 (2003).
75. Shahzad, M. M. K. et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol. Ther. 8, 1027-1034 (2009).
76. Hogrefe, R. I. et al. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25, 889-907 (2006).
77. Ferrari, M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotech. 28, 181-188 (2010).
78. Estévez, M. C. et al. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Methods Mol. Biol. 624, 235-248 (2010).
79. Kim, S. H., Mok, H., Jeong, J. H., Kim, S. W. & Park, T. G. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem. 17, 241-244 (2006).
80. Passarella, R. J. et al. Targeted nanoparticles that deliver a sustained, specific release of paclitaxel to irradiated tumors. Cancer Res. 70, 4550-4559 (2010).
81. Tanaka, T. et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 70, 3687-3696 (2010).
82. Decuzzi, P. & Ferrari, M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 29, 377-384 (2008).
83. Ferrari, M. The mathematical engines of nanomedicine. Small 4, 20-25 (2008).
84. Sanga, S. et al. Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev. Anticancer Ther. 6, 1361-1376 (2006).
85. Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
86. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
87. Thall, P. F. & Cook, J. D. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693 (2004).
88. Bruchez, M. J., Moronne, M., Gin, P., Weiss, S. & Alivisatos, A. P. Semiconductor nanocrystals as fluorescent biological labels. Science 281, 2013-2016 (1998).
89. Tan, W. B., Jiang, S. & Zhang, Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28, 1565-1571 (2007).
90. Tavares, A. J., Chong, L., Petryayeva, E., Algar, W. R. & Krull, U. J. Quantum dots as contrast agents for in vivo tumor imaging: progress and issues. Anal. Bioanal. Chem. 25 Jul 2010 (doi:10.1007/ s00216-010-4010-3).
91. Hong, H., Zhang, Y. & Cai, W. In vivo imaging of RNA interference. J. Nucl. Med. 51, 169-172 (2010).
92. Chen, X. Q. et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 6, 3823-3826 (2000).
93. Kopreski, M. S., Benko, F. A., Kwak, L. W. & Gocke, C. D. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res. 5, 1961-1965 (1999).
94. Swarup, V. & Rajeswari, M. R. Circulating (cell-free) nucleic acids - a promising, non-invasive tool for early detection of several human diseases. FEBS J. 581, 795-799 (2007).
95. Abdrakhmanova, A. et al. RNAi and iTRAQ reagents united: targeted quantitation of siRNA-mediated protein silencing in human cells. Anal. Bioanal. Chem. 395, 773-785 (2009).
96. Spielman, R. S. et al. Common genetic variants account for differences in gene expression among ethnic groups. Nature Genet. 39, 226-231 (2007).
97. Nicoloso, M. S. et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 70, 2789-2798 (2010).
98. Merritt, W. M., Bar-Eli, M. & Sood, A. K. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 70, 2571-2574 (2010).
99. Diederichs, S. et al. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc. Natl Acad. Sci. USA 105, 9284-9289 (2008).